

PRESS RELEASE

Date 22 January 2019
Contact Investor Relations: Felix Burkhard, CFO, Galenica Group
Media Relations: Christina Hertig, Head Corporate Communications, Galenica Group
Subject Change to the Board of Directors of the Galenica Group

Change to the Board of Directors of the Galenica Group: Daniela Bosshardt-Hengartner proposed as the new Chairwoman of the Board of Directors

At the Annual General Meeting on 2 May 2019, the Board of Directors of the Galenica Group will propose Daniela Bosshardt-Hengartner to shareholders for election as Chairwoman of the Board of Directors. The current Chairman of the Board of Directors, Jörg Kneubühler, has decided to step down from his position at this time to focus on new projects. The Board of Directors will also propose Markus R. Neuhaus to shareholders for election as a new member of the Board.

Jörg Kneubühler, who has chaired the Galenica Group since the initial public offering (IPO) in April 2017, has decided to step down from his position at the Annual General Meeting on 2 May 2019, and will no longer stand for re-election as a member of the Board of Directors. After successfully leading the Galenica Group to independence following the IPO two years ago, he now wants to devote his time to new projects. The Board of Directors respects his decision and would like to thank Jörg Kneubühler for his tremendous and valuable contribution.

The Board of Directors will propose Daniela Bosshardt-Hengartner to shareholders for election as the new Chairwoman. Daniela Bosshardt-Hengartner is currently the Deputy Chairwoman of the Board of Directors, Chairwoman of the Remuneration Committee and a member of the Audit & Risk Committee.

Daniela Bosshardt-Hengartner: Studied pharmacy at the ETH, with many years of experience as a member of the Galenica Board of Directors

The Board of Directors is convinced that Daniela Bosshardt-Hengartner is the ideal candidate for Chairwoman of the Galenica Group. In addition to her education as a pharmacist, she has sound financial expertise and a wealth of experience as a management consultant. Combined with her many years of service as a member of the Board of Directors of Galenica and other companies, Daniela Bosshardt-Hengartner has the desired and necessary skills and experience, making her an ideal fit for the role of Chairwoman of the Board of Directors.

Jörg Kneubühler: Valuable contribution to the IPO and successful positioning of Galenica

Before becoming Chairman of the Galenica Group, Jörg Kneubühler worked in operations at Galenica for 15 years: after joining the former Galenica Group in 2002 as Head of Finance and Administration of Vifor Pharma, he became Head of Controlling for the Galenica Group in 2006 and Head of Corporate Finance and Controlling for the Galenica Group and a member of the Corporate Executive Committee in 2009. In 2012, he took on the role of CFO and from 2014 to April 2017, he additionally served as CEO of Galenica Santé before becoming Chairman of the Board of Directors after the IPO.

Date 22 January 2019
Page 2/2
Subject Change to the Board of Directors of the Galenica Group

Jörg Kneubühler has played a major role in ensuring the successful development of the Galenica Group. The Board of Directors would like to thank him in particular for his valuable contribution to the IPO and the successful positioning of Galenica as an independent company, and wishes him all the best and much satisfaction for the future. Jörg Kneubühler will continue to support the Board of Directors in an advisory capacity for one year.

Markus R. Neuhaus: Extensive expertise in finance and economics

The Board of Directors will also propose Markus R. Neuhaus to shareholders for election as a new member of the Board at the next Annual General Meeting. Markus R. Neuhaus, who has a PhD in law and is a certified tax expert, will be an excellent addition to the Board of Directors of the Galenica Group thanks to his extensive expertise in finance and economics. He also has many years of consulting experience in the areas of corporate strategy and governance as well as an extensive network in the worlds of business and politics in Switzerland.

For further information, please contact:

Christina Hertig, Head Corporate Communications
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Felix Burkhard, CFO
Tel. +41 58 852 85 29
E-mail: investors@galenica.com

Curriculum vitae

Daniela Bosshardt-Hengartner (born 1972, Swiss citizen) joined the Board of Directors of the former Galenica Ltd. in 2008. She has a Federal Diploma in Pharmacy from the Federal Institute of Technology (ETH) Zurich, and started her career as a pharmacist. From 1998 to 2002, she worked as a financial analyst at Bank am Bellevue before moving to M2 Capital from 2003 to 2004. She has been working as a management consultant in the pharmaceutical sector since 2004. She is also a member of the Board of Directors of RepRisk AG (Zurich), Vifor Pharma Ltd. (Zurich) and investiere.ch (Baar).

Dr. Markus R. Neuhaus (born 1958, Swiss citizen) studied law at the University of Zurich, where he gained his master's degree and doctorate. He started his career in 1985 at PwC Switzerland, where he held various roles both in PwC Switzerland and PwC Global, including as CEO of PricewaterhouseCoopers AG from 2003 to 2012. Since 2012, he has served as Chairman of the Board of Directors of PricewaterhouseCoopers AG and a member of the Supervisory Board of PwC Europe SE. His mandate on the Board of Directors of PwC will end in June 2019. Markus R. Neuhaus is also Vice Chairman of Avenir Suisse, Vice Chairman of the Executive Committee of Zürcher Handelskammer and a member of the Board of Economiesuisse and Expertsuisse (formerly Treuhandkammer).

Galenica is the leading fully integrated healthcare provider in Switzerland. With 500 own, joint venture and independent partner pharmacies, Galenica operates the largest network of pharmacies in Switzerland. In addition, Galenica further develops and offers well-known own brands and products, exclusive brands and products from business partners as well as a variety of on-site health services and tests for customers. Galenica is also the leading provider of pre-wholesale and wholesale services as well as database services in the Swiss healthcare market. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446).

Additional information concerning Galenica can be found at www.galenica.com